 Leigh Perreault
Concepts (337)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prediabetic State | 24 | 2024 | 253 | 6.710 |
Why?
| | Diabetes Mellitus, Type 2 | 50 | 2024 | 2531 | 4.880 |
Why?
| | Insulin Resistance | 34 | 2025 | 1208 | 4.160 |
Why?
| | Hypoglycemic Agents | 23 | 2023 | 1291 | 3.090 |
Why?
| | Obesity | 30 | 2025 | 2992 | 2.780 |
Why?
| | Blood Glucose | 31 | 2023 | 2186 | 2.520 |
Why?
| | Weight Loss | 16 | 2025 | 787 | 2.300 |
Why?
| | Muscle, Skeletal | 22 | 2025 | 1724 | 2.260 |
Why?
| | Cardiovascular Diseases | 15 | 2020 | 2111 | 1.970 |
Why?
| | Insulin | 20 | 2024 | 2409 | 1.800 |
Why?
| | Sphingolipids | 7 | 2024 | 77 | 1.660 |
Why?
| | Diabetes Mellitus | 11 | 2023 | 1040 | 1.590 |
Why?
| | Triglycerides | 11 | 2024 | 524 | 1.550 |
Why?
| | Benzhydryl Compounds | 3 | 2017 | 73 | 1.440 |
Why?
| | Glucose Intolerance | 8 | 2020 | 146 | 1.430 |
Why?
| | Diabetic Angiopathies | 3 | 2017 | 259 | 1.410 |
Why?
| | Diglycerides | 6 | 2024 | 61 | 1.290 |
Why?
| | Diabetes Complications | 2 | 2019 | 227 | 1.100 |
Why?
| | Overweight | 7 | 2022 | 558 | 1.090 |
Why?
| | Glucosides | 2 | 2017 | 44 | 1.060 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2023 | 135 | 0.980 |
Why?
| | Life Style | 12 | 2020 | 490 | 0.970 |
Why?
| | Exercise | 12 | 2025 | 2057 | 0.950 |
Why?
| | Metformin | 13 | 2023 | 331 | 0.890 |
Why?
| | Primary Health Care | 6 | 2023 | 1738 | 0.880 |
Why?
| | Receptors, Gastrointestinal Hormone | 1 | 2023 | 9 | 0.850 |
Why?
| | Anti-Obesity Agents | 2 | 2024 | 57 | 0.840 |
Why?
| | Adipose Tissue | 5 | 2025 | 635 | 0.840 |
Why?
| | Glucose Tolerance Test | 15 | 2021 | 366 | 0.830 |
Why?
| | Cannabidiol | 1 | 2025 | 119 | 0.810 |
Why?
| | Glucose Clamp Technique | 11 | 2024 | 195 | 0.800 |
Why?
| | Adult | 56 | 2025 | 37929 | 0.790 |
Why?
| | Goals | 2 | 2021 | 170 | 0.780 |
Why?
| | Dronabinol | 1 | 2025 | 226 | 0.770 |
Why?
| | Humans | 96 | 2025 | 137585 | 0.770 |
Why?
| | Nutrition Therapy | 1 | 2022 | 37 | 0.730 |
Why?
| | Marijuana Use | 1 | 2025 | 206 | 0.720 |
Why?
| | Middle Aged | 46 | 2025 | 33479 | 0.720 |
Why?
| | Health Equity | 1 | 2023 | 99 | 0.710 |
Why?
| | Liver | 4 | 2014 | 1943 | 0.690 |
Why?
| | Primary Care Nursing | 1 | 2019 | 4 | 0.650 |
Why?
| | Hyperglycemia | 4 | 2014 | 347 | 0.650 |
Why?
| | Male | 61 | 2025 | 67762 | 0.650 |
Why?
| | Female | 66 | 2025 | 73304 | 0.630 |
Why?
| | Lipid Metabolism | 5 | 2025 | 518 | 0.600 |
Why?
| | Obesity Management | 1 | 2018 | 8 | 0.590 |
Why?
| | Insulin, Long-Acting | 1 | 2019 | 63 | 0.590 |
Why?
| | Peripheral Vascular Diseases | 1 | 2019 | 103 | 0.590 |
Why?
| | Microvessels | 1 | 2019 | 88 | 0.580 |
Why?
| | Infant, Newborn, Diseases | 1 | 2019 | 113 | 0.580 |
Why?
| | Awareness | 1 | 2019 | 103 | 0.570 |
Why?
| | Body Mass Index | 12 | 2024 | 2389 | 0.570 |
Why?
| | Cannabis | 1 | 2025 | 494 | 0.560 |
Why?
| | Fasting | 4 | 2020 | 281 | 0.550 |
Why?
| | Ceramides | 5 | 2024 | 118 | 0.540 |
Why?
| | Policy | 1 | 2018 | 150 | 0.530 |
Why?
| | Precision Medicine | 1 | 2021 | 429 | 0.530 |
Why?
| | Weight Reduction Programs | 2 | 2017 | 117 | 0.530 |
Why?
| | Risk Management | 1 | 2017 | 93 | 0.520 |
Why?
| | Incretins | 2 | 2021 | 22 | 0.510 |
Why?
| | Risk Factors | 19 | 2023 | 10388 | 0.510 |
Why?
| | Rest | 2 | 2017 | 121 | 0.510 |
Why?
| | Choristoma | 1 | 2015 | 21 | 0.490 |
Why?
| | Sleep Deprivation | 5 | 2021 | 174 | 0.480 |
Why?
| | Insulin-Secreting Cells | 2 | 2010 | 377 | 0.450 |
Why?
| | Weight Gain | 4 | 2019 | 519 | 0.430 |
Why?
| | Inflammation | 1 | 2025 | 2837 | 0.430 |
Why?
| | Sarcolemma | 3 | 2024 | 43 | 0.410 |
Why?
| | Glucose | 4 | 2023 | 1020 | 0.400 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1477 | 0.390 |
Why?
| | Phenols | 1 | 2013 | 99 | 0.390 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1050 | 0.390 |
Why?
| | Lipids | 4 | 2024 | 672 | 0.390 |
Why?
| | Physical Endurance | 5 | 2020 | 275 | 0.360 |
Why?
| | Fenofibrate | 1 | 2011 | 28 | 0.350 |
Why?
| | Glucagon-Like Peptides | 2 | 2022 | 58 | 0.340 |
Why?
| | Athletes | 7 | 2024 | 423 | 0.340 |
Why?
| | Hypolipidemic Agents | 1 | 2011 | 91 | 0.330 |
Why?
| | Phosphatidylcholines | 2 | 2024 | 147 | 0.330 |
Why?
| | Palmitates | 1 | 2009 | 18 | 0.330 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 47 | 0.330 |
Why?
| | Cross-Sectional Studies | 9 | 2024 | 5472 | 0.320 |
Why?
| | Pyrazines | 1 | 2010 | 90 | 0.320 |
Why?
| | Hospitalization | 1 | 2019 | 2199 | 0.320 |
Why?
| | Aged | 17 | 2023 | 23961 | 0.310 |
Why?
| | Triazoles | 1 | 2010 | 147 | 0.310 |
Why?
| | Energy Metabolism | 4 | 2021 | 922 | 0.290 |
Why?
| | Young Adult | 13 | 2025 | 13209 | 0.290 |
Why?
| | Sleep | 4 | 2021 | 755 | 0.290 |
Why?
| | Biomarkers | 8 | 2023 | 4149 | 0.290 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2017 | 24 | 0.270 |
Why?
| | Risk Reduction Behavior | 3 | 2023 | 220 | 0.270 |
Why?
| | Diabetic Nephropathies | 2 | 2020 | 294 | 0.260 |
Why?
| | Sex Characteristics | 3 | 2021 | 762 | 0.260 |
Why?
| | Markov Chains | 2 | 2018 | 126 | 0.260 |
Why?
| | Absenteeism | 2 | 2018 | 49 | 0.260 |
Why?
| | Double-Blind Method | 5 | 2024 | 1993 | 0.260 |
Why?
| | Health Services | 2 | 2018 | 107 | 0.250 |
Why?
| | Sex Factors | 5 | 2018 | 2071 | 0.250 |
Why?
| | Adiponectin | 3 | 2018 | 244 | 0.240 |
Why?
| | Pilot Projects | 2 | 2021 | 1710 | 0.230 |
Why?
| | Remission Induction | 3 | 2019 | 288 | 0.230 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5131 | 0.230 |
Why?
| | Muscle Fibers, Skeletal | 3 | 2024 | 218 | 0.230 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2022 | 617 | 0.230 |
Why?
| | Circadian Rhythm | 3 | 2019 | 468 | 0.220 |
Why?
| | Carnitine | 2 | 2024 | 84 | 0.220 |
Why?
| | Lipogenesis | 2 | 2017 | 61 | 0.220 |
Why?
| | Dietary Fats | 3 | 2020 | 304 | 0.220 |
Why?
| | Lipoprotein Lipase | 1 | 2004 | 59 | 0.210 |
Why?
| | Hyperinsulinism | 1 | 2024 | 121 | 0.200 |
Why?
| | Physical Exertion | 1 | 2004 | 215 | 0.200 |
Why?
| | Oxidation-Reduction | 4 | 2024 | 1060 | 0.200 |
Why?
| | Healthy Lifestyle | 1 | 2023 | 34 | 0.200 |
Why?
| | Computer Simulation | 2 | 2018 | 978 | 0.200 |
Why?
| | Diet, Reducing | 3 | 2017 | 89 | 0.190 |
Why?
| | Energy Intake | 4 | 2021 | 485 | 0.190 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 1289 | 0.190 |
Why?
| | Consensus | 3 | 2020 | 683 | 0.190 |
Why?
| | Biopsy | 3 | 2018 | 1129 | 0.190 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1236 | 0.190 |
Why?
| | Cluster Analysis | 1 | 2023 | 499 | 0.180 |
Why?
| | Endpoint Determination | 2 | 2019 | 77 | 0.180 |
Why?
| | Prevalence | 2 | 2019 | 2734 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2024 | 2057 | 0.180 |
Why?
| | Nephrology | 1 | 2022 | 61 | 0.180 |
Why?
| | Glucose Transporter Type 4 | 1 | 2021 | 40 | 0.180 |
Why?
| | Cytosol | 2 | 2020 | 226 | 0.180 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 232 | 0.170 |
Why?
| | Body Weight | 4 | 2024 | 985 | 0.170 |
Why?
| | Risk Adjustment | 1 | 2020 | 78 | 0.170 |
Why?
| | Endocrinologists | 1 | 2020 | 13 | 0.160 |
Why?
| | New Zealand | 1 | 2019 | 56 | 0.160 |
Why?
| | Cytosine | 1 | 2019 | 49 | 0.160 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 65 | 0.160 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 265 | 0.160 |
Why?
| | Fatty Liver | 1 | 2021 | 243 | 0.150 |
Why?
| | Liraglutide | 1 | 2019 | 30 | 0.150 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2019 | 159 | 0.150 |
Why?
| | Exercise Test | 3 | 2015 | 625 | 0.150 |
Why?
| | Models, Econometric | 1 | 2018 | 34 | 0.150 |
Why?
| | Retinal Diseases | 1 | 2019 | 91 | 0.150 |
Why?
| | Postprandial Period | 1 | 2019 | 107 | 0.140 |
Why?
| | Quinolizines | 1 | 1997 | 9 | 0.140 |
Why?
| | Adolescent | 8 | 2023 | 21513 | 0.140 |
Why?
| | United States | 9 | 2023 | 14841 | 0.140 |
Why?
| | Drug Combinations | 1 | 2019 | 343 | 0.140 |
Why?
| | Colorado | 3 | 2023 | 4565 | 0.140 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 224 | 0.140 |
Why?
| | Antiemetics | 1 | 1997 | 43 | 0.140 |
Why?
| | Referral and Consultation | 1 | 2023 | 786 | 0.140 |
Why?
| | Nausea | 1 | 1997 | 111 | 0.140 |
Why?
| | Health Resources | 1 | 2018 | 120 | 0.130 |
Why?
| | Cholesterol, HDL | 2 | 2015 | 203 | 0.130 |
Why?
| | Cytokines | 1 | 2025 | 2085 | 0.130 |
Why?
| | Vomiting | 1 | 1997 | 130 | 0.130 |
Why?
| | Hysterectomy | 1 | 1997 | 129 | 0.130 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2828 | 0.130 |
Why?
| | Odds Ratio | 1 | 2019 | 1070 | 0.130 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 307 | 0.130 |
Why?
| | Patient-Centered Care | 1 | 2021 | 530 | 0.120 |
Why?
| | Patient Participation | 1 | 2019 | 420 | 0.120 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 77 | 0.120 |
Why?
| | Blotting, Western | 2 | 2016 | 1226 | 0.120 |
Why?
| | Eating | 2 | 2021 | 380 | 0.120 |
Why?
| | Phenotype | 1 | 2024 | 3196 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 951 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 532 | 0.120 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 591 | 0.120 |
Why?
| | Treatment Outcome | 6 | 2021 | 10811 | 0.120 |
Why?
| | Research Design | 2 | 2019 | 1139 | 0.120 |
Why?
| | Kidney Diseases | 1 | 2019 | 408 | 0.120 |
Why?
| | Exercise Therapy | 2 | 2017 | 443 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 213 | 0.110 |
Why?
| | Patient Compliance | 1 | 2019 | 581 | 0.110 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 88 | 0.110 |
Why?
| | Indoles | 1 | 1997 | 412 | 0.110 |
Why?
| | Hypoglycemia | 1 | 2019 | 445 | 0.110 |
Why?
| | Income | 1 | 2015 | 202 | 0.110 |
Why?
| | Somatostatin | 1 | 2014 | 61 | 0.110 |
Why?
| | Logistic Models | 1 | 2019 | 2074 | 0.110 |
Why?
| | Employment | 1 | 2015 | 178 | 0.100 |
Why?
| | Recovery of Function | 2 | 2015 | 653 | 0.100 |
Why?
| | Pneumonia | 1 | 2019 | 639 | 0.100 |
Why?
| | Fructose | 1 | 2014 | 112 | 0.100 |
Why?
| | Health Personnel | 1 | 2019 | 710 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2014 | 108 | 0.100 |
Why?
| | Smoking | 2 | 2012 | 1627 | 0.100 |
Why?
| | Cost of Illness | 1 | 2015 | 308 | 0.100 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 310 | 0.100 |
Why?
| | C-Reactive Protein | 1 | 2015 | 410 | 0.100 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 54 | 0.100 |
Why?
| | Oxygen Consumption | 4 | 2016 | 696 | 0.100 |
Why?
| | Qualitative Research | 1 | 2019 | 1386 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2016 | 578 | 0.090 |
Why?
| | Homeostasis | 1 | 2016 | 621 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2019 | 7635 | 0.090 |
Why?
| | Adult Children | 1 | 2011 | 24 | 0.090 |
Why?
| | Prospective Studies | 3 | 2019 | 7604 | 0.090 |
Why?
| | Depressive Disorder, Major | 1 | 2015 | 364 | 0.090 |
Why?
| | Placebos | 2 | 2009 | 199 | 0.090 |
Why?
| | Mitochondria | 1 | 2018 | 948 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1587 | 0.090 |
Why?
| | Adipocytes | 1 | 2012 | 222 | 0.090 |
Why?
| | Health Behavior | 2 | 2023 | 762 | 0.090 |
Why?
| | Diabetes, Gestational | 1 | 2015 | 318 | 0.090 |
Why?
| | Age Factors | 1 | 2018 | 3295 | 0.090 |
Why?
| | Sitagliptin Phosphate | 1 | 2010 | 33 | 0.080 |
Why?
| | Family Health | 1 | 2011 | 196 | 0.080 |
Why?
| | Comorbidity | 1 | 2015 | 1622 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 1329 | 0.080 |
Why?
| | Metabolomics | 1 | 2015 | 678 | 0.080 |
Why?
| | Longevity | 1 | 2011 | 165 | 0.080 |
Why?
| | C-Peptide | 1 | 2010 | 163 | 0.080 |
Why?
| | Mitochondria, Muscle | 2 | 2021 | 116 | 0.080 |
Why?
| | Quality of Life | 3 | 2019 | 2892 | 0.080 |
Why?
| | Disease Progression | 3 | 2024 | 2757 | 0.080 |
Why?
| | Menopause | 1 | 2011 | 320 | 0.070 |
Why?
| | Leisure Activities | 1 | 2008 | 33 | 0.070 |
Why?
| | Delphi Technique | 2 | 2019 | 280 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1786 | 0.070 |
Why?
| | Body Composition | 1 | 2011 | 684 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2031 | 0.060 |
Why?
| | Risk Assessment | 3 | 2015 | 3457 | 0.060 |
Why?
| | Fibrinogen | 2 | 2018 | 168 | 0.060 |
Why?
| | Cohort Studies | 4 | 2021 | 5742 | 0.060 |
Why?
| | Postoperative Complications | 1 | 1997 | 2654 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1509 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2012 | 3715 | 0.060 |
Why?
| | Mass Screening | 1 | 2013 | 1287 | 0.060 |
Why?
| | Regression Analysis | 2 | 2019 | 1024 | 0.060 |
Why?
| | Aging | 1 | 2015 | 1864 | 0.060 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 115 | 0.050 |
Why?
| | Health Expenditures | 1 | 1986 | 189 | 0.050 |
Why?
| | Incidence | 3 | 2019 | 2804 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1774 | 0.050 |
Why?
| | Prognosis | 2 | 2023 | 4030 | 0.050 |
Why?
| | Hormones | 1 | 2004 | 143 | 0.050 |
Why?
| | Depression | 1 | 2012 | 1397 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2019 | 15657 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2003 | 133 | 0.050 |
Why?
| | Parents | 1 | 2011 | 1347 | 0.050 |
Why?
| | Eligibility Determination | 1 | 2023 | 65 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5757 | 0.050 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 209 | 0.050 |
Why?
| | Wakefulness | 2 | 2015 | 125 | 0.050 |
Why?
| | Alcohol Drinking | 1 | 2009 | 828 | 0.050 |
Why?
| | Lactic Acid | 1 | 2003 | 305 | 0.050 |
Why?
| | Animals | 3 | 2024 | 36940 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1266 | 0.050 |
Why?
| | Acute Disease | 1 | 2024 | 1007 | 0.040 |
Why?
| | Citric Acid Cycle | 1 | 2021 | 57 | 0.040 |
Why?
| | Subcellular Fractions | 1 | 2021 | 82 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 157 | 0.040 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 59 | 0.040 |
Why?
| | Kinetics | 1 | 2004 | 1670 | 0.040 |
Why?
| | Protective Agents | 1 | 2020 | 41 | 0.040 |
Why?
| | Motor Activity | 2 | 2015 | 718 | 0.040 |
Why?
| | Education | 1 | 2020 | 108 | 0.040 |
Why?
| | Proprotein Convertase 9 | 1 | 2020 | 73 | 0.040 |
Why?
| | Stearoyl-CoA Desaturase | 2 | 2010 | 65 | 0.040 |
Why?
| | Poisson Distribution | 1 | 2019 | 75 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2013 | 1316 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2019 | 78 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 6828 | 0.040 |
Why?
| | E-Selectin | 1 | 2018 | 57 | 0.040 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2018 | 31 | 0.040 |
Why?
| | Pregnancy | 2 | 2015 | 6763 | 0.040 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 81 | 0.040 |
Why?
| | Probability | 1 | 2019 | 304 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2018 | 115 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 139 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2019 | 91 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2020 | 620 | 0.030 |
Why?
| | Research | 1 | 2020 | 451 | 0.030 |
Why?
| | Leptin | 1 | 2018 | 236 | 0.030 |
Why?
| | Diet | 3 | 2012 | 1278 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2017 | 3556 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 418 | 0.030 |
Why?
| | Adaptation, Physiological | 2 | 2010 | 553 | 0.030 |
Why?
| | Metabolome | 1 | 2019 | 350 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 452 | 0.030 |
Why?
| | Rats | 1 | 2024 | 5647 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 99 | 0.030 |
Why?
| | Diet, Fat-Restricted | 1 | 2015 | 79 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2013 | 2844 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 150 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2018 | 778 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2020 | 641 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1468 | 0.030 |
Why?
| | Calorimetry | 1 | 2013 | 70 | 0.030 |
Why?
| | Fatty Acids | 1 | 2016 | 443 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2012 | 59 | 0.020 |
Why?
| | Risk | 1 | 2015 | 912 | 0.020 |
Why?
| | Glycerol | 1 | 2012 | 94 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2015 | 286 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1704 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2833 | 0.020 |
Why?
| | Calorimetry, Indirect | 1 | 2010 | 84 | 0.020 |
Why?
| | Antidepressive Agents | 1 | 2012 | 236 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 991 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2010 | 41 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5778 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 334 | 0.020 |
Why?
| | Retinoid X Receptor gamma | 1 | 2009 | 4 | 0.020 |
Why?
| | Polysomnography | 1 | 2010 | 185 | 0.020 |
Why?
| | PPAR alpha | 1 | 2009 | 58 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2607 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 412 | 0.020 |
Why?
| | Bicycling | 1 | 2010 | 114 | 0.020 |
Why?
| | Coronary Disease | 1 | 2011 | 385 | 0.020 |
Why?
| | Women's Health | 1 | 2011 | 372 | 0.020 |
Why?
| | Phospholipids | 1 | 2010 | 223 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1759 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 816 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 976 | 0.020 |
Why?
| | Adiposity | 1 | 2012 | 518 | 0.020 |
Why?
| | Mice | 1 | 2024 | 17787 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2426 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2011 | 766 | 0.020 |
Why?
| | Infant Care | 1 | 1986 | 45 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1916 | 0.020 |
Why?
| | Infertility | 1 | 1986 | 55 | 0.010 |
Why?
| | Health Promotion | 1 | 2011 | 741 | 0.010 |
Why?
| | Delivery, Obstetric | 1 | 1986 | 144 | 0.010 |
Why?
| | Maternal Health Services | 1 | 1986 | 98 | 0.010 |
Why?
| | Follicular Phase | 1 | 2003 | 39 | 0.010 |
Why?
| | Anaerobic Threshold | 1 | 2003 | 28 | 0.010 |
Why?
| | Contraception | 1 | 1986 | 161 | 0.010 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2003 | 86 | 0.010 |
Why?
| | Abortion, Induced | 1 | 1986 | 105 | 0.010 |
Why?
| | Luteal Phase | 1 | 2003 | 45 | 0.010 |
Why?
| | Catecholamines | 1 | 2003 | 98 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2189 | 0.010 |
Why?
| | Heart Rate | 1 | 2003 | 822 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1986 | 6079 | 0.010 |
Why?
|
|
Perreault's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|